Neuren Pharmaceuticals Limited · ASX:NEU
Neuren Pharmaceuticals — FY2024 Earnings Presentation
12 slides from Neuren Pharmaceuticals's earnings presentation, Feb 28, 2025
Slide 1: 2024 Full Year Results Webinar
2024 Full Year Results Webinar 28 Feb 2025 IMPROVING THE LIVES OF PEOPLE WITH NEURODEVELOPMENTAL DISABILITIES Pa g e□1
Slide 2: Forward looking statements
Forward looking statements This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Neuren can give no assurance that these expectations will prove to
Slide 3: Large potential upside for shareholders is enabled by financial strength
Large potential upside for shareholders is enabled by financial strength Maximise value of NNZ-2591 as a multiple indication platform Positive Phase 2 results for Phelan-McDermid syndrome Positive Phase 2 results for Pitt Hopkins syndrome Value Positive Phase 2 results for Angelman syndrome Lo
Slide 4: The 2024 numbers – a record year of income for shareholders
The 2024 numbers – a record year of income for shareholders Comprehensive income (CI) CI margin Total comprehensive income (A$m) A$166m 73% 166.2 157.1 NPAT FX gain A$142m A$24m Corporate & admin costs R&D investment in NNZ-2591 A$5m A$33m DAYBUE revenue 23 & 24 Pro-forma cash 0.2 A$445m A$359m 2022
Slide 5: Record high cash reserve organically generated to fund growth
Record high cash reserve organically generated to fund growth Cash and Pro-forma Cash (A$m) 18.7 80.5 359.4 -38.5 76.5 222.2 Cash at 31 Dec 24 PRV Sales milestone Q4 24 royalty Q4 24 tax paid Q1 25* Pro-forma cash * Includes US withholding tax on Q4 24 royalty and sales milestone payment 5
Slide 6: Growing sustainable income for Neuren from DAYBUE in US
Growing sustainable income for Neuren from DAYBUE in US DAYBUE US Net Sales (US$m) US Royalty to Neuren (A$m) + 9-16% 405 + 11-19% 348 67 + 97% 380 56 + 110% 62 177 27 CY2023 (Apr - CY2024 CY2025 Acadia CY2023 CY2024 CY2025E* Dec) Guidance * Based on CY25 Acadia DAYBUE US Net Sales Guidance of US$38
Slide 7: Q4 2024 was a record quarter of DAYBUE sales since launch in the US
Q4 2024 was a record quarter of DAYBUE sales since launch in the US US Net Sales (US$m) Significant further growth potential in the US1: CY24 DAYBUE US$350m (up 97% y-o-y) • Diagnosed population expanding towards CY23 DAYBUE US$177m prevalence of 6,000-9,000 97 Currently 5,500–5,800 diagnosed patien
Slide 8: Long term growth opportunity for trofinetide through global expansion
Long term growth opportunity for trofinetide through global expansion Canada 600 - 900 Rett patients1 Approved in Oct 2024 Europe First sales in Q3 2025 9,000 - 12,000 Rett patients1 US MAA filed with potential approval Japan Q1 2026 6,000 - 9,000 Rett patients1 1,000 - 2,000 Rett patients1 Initiati
Slide 9: Economics to Neuren from Acadia partnership
Economics to Neuren from Acadia partnership North America Outside North America US$10m upfront in 2018 US$100m upfront in 2023 US$10m in 2022 following acceptance of NDA for review US$35m following 1st commercial sale in Europe US$40m in 2023 following 1st commercial sale in the US US$15m fo
Slide 10: Leveraging trofinetide experience into multiple indications for NNZ-2591
Leveraging trofinetide experience into multiple indications for NNZ-2591 Most advanced clinical program in PMS and PTHS, oral therapy competitive in AS Indications Orphan Rare Fast Positive Positive Commence Phase 3 Pediatric Track Phase 2 EoP2 Meeting Phelan-McDermid Plan for mid year syndrome (PMS
Slide 11: Key milestones met and targeted
Key milestones met and targeted Milestones Achieved in 2024 2025 Milestones CY2024 DAYBUE net sales of ~US$348m in the US, Submission by Acadia of EU marketing application for trofinetide generated A$56m royalties to Neuren and exceeded • First sales by Acadia of DAYBUE in Canada (Q3 2025) thres
Slide 12: Contact
CONTACT [email protected] Authorised by the CEO & Managing Director of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124 12
Neuren Pharmaceuticals — FY2024 Earnings Presentation on 6ix